SCHEMBL21882580

SCHEMBL21882580

Cc1ccc(S(=O)(=O)NC(=O)c2cccc(C(C)C)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 3/20 0.61
PTGS2 P35354 4/20 0.57
EGFR P00533 2/20 0.56
PTGS1 P23219 1/20 0.55
HTT P42858 2/20 0.54
PSMB8 P28062 1/20 0.54
PSMB5 P28074 1/20 0.54
FLT1 P17948 2/20 0.53
FLT4 P35916 2/20 0.53
KDR P35968 2/20 0.53
POLB P06746 2/20 0.53
GAA P10253 1/20 0.53
NLRP3 Q96P20 1/20 0.52
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119239 0.86 KAT6A (0.57) KAT6AHTTPSMB8PSMB5FLT1
SCHEMBL9179605 0.84 PTGS2 (0.64) KAT6APTGS2EGFRPTGS1FLT1
SCHEMBL10769381 0.82 PTGS2 (0.65) PTGS2EGFRPTGS1FLT1FLT4
SCHEMBL6641114 0.81 KMT2A (0.60) KAT6APTGS2EGFRPTGS1FLT1
SCHEMBL13209252 0.80 KAT6A (0.58) KAT6AHTTGAAKMT2ALMNA
SCHEMBL5931087 0.79 PTGS2 (0.71) PTGS2EGFRPTGS1HTTFLT1
SCHEMBL23447722 0.78 FFAR1 (0.61) KAT6APTGS2EGFRPTGS1HTT
SCHEMBL3292237 0.78 PTGS2 (0.69) PTGS2EGFRPTGS1HTTFLT1
SCHEMBL9176194 0.78 KAT6A (0.64) KAT6APTGS2EGFRPTGS1POLB
SCHEMBL9176266 0.77 PTGS2 (0.78) PTGS2EGFRPTGS1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 KAT6A 2864/4885PTGS2 1196/4885EGFR 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.